MedTrace Logo

Levagen+ Efficacy Study on Diabetic Peripheral Neuropathy

NCT07028528 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-07-23

No results posted yet for this study

Summary

The goal of this clinical trial is to assess the efficacy of Levagen+ supplementation for the symptoms of diabetic peripheral neuropathy (DPN) in patients with DPN.

Participants will have remote visits and attend a local pathology centre for blood draws. They will take the study product for 12 weeks, from baseline to week 12 they will have remote visits every 3 weeks.

Conditions

  • Diabetic Peripheral Neuropathy

Interventions

DIETARY_SUPPLEMENT

Levagen+

Participants will take 1 capsule twice daily with water after food. Each capsule will contain: A175mg containing 150 mg of palmitoylethanolamide (PEA). Total daily dose of 350mg Levagen+ containing 300 mg PEA

OTHER

Placebo

Participants will take 1 capsule twice daily with water after food. Each capsule will contain microcrystalline cellulose \[MCC\]

Sponsors & Collaborators

  • Gencor Pacific Limited

    collaborator UNKNOWN

  • RDC Clinical Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Ramasamy Venkatesh · Gencor Pacific

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07028528 on ClinicalTrials.gov